Advanced Search


Study ID Status Title Patient Level Data
109817 Completed Evaluate the reactogenicity & immunogenicity of 1 or 2 booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in primed adults aged between 19 & 61 years Study Listed on
109821 Completed Observer blind study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals influenza vaccine GSK576389A administered to adults over 65 years previously vaccinated with the same vaccine, compared to Fluarix™ Study Listed on
109823 Completed Safety and immunogenicity of Cervarix™ in human immunodeficiency virus infected females
109825 Completed Safety and immunogenicity of GSK Biologicals’ (pre-) pandemic influenza candidate vaccine (GSK1562902A) in children aged 6 to 35 months Study Listed on
109835 Completed Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children Study Listed on
109836 Completed A multicentre study to evaluate the safety and immunogenicity of GSK Biologicals’ HPV vaccine (GSK1674330A) in healthy female subjects aged 18–25 years. Study Listed on
109861 Completed Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix Study Listed on
109937 Completed Analysis of the incidence of expression of tumor antigens MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME in pathologically proven stage I, II and III Non-Small Cell Lung cancer in Asiatic patients
109995 Completed A phase IIIb, open, randomised, multicentre, primary study in healthy children, to establish the non-inferiority of GlaxoSmithKline (GSK) Biologicals’ MeMuRu-OKA vaccine (administered at 9 and 15 months of age) versus Priorix™ (9 months of age) and Priorix™ co-administered with Varilrix™ at 15 months of age (comparator) and also to evaluate the non-inferiority of Priorix™ (9 months of age) and MeMuRu-OKA vaccine (15 months of age) versus the comparator, all administered subcutaneously as two-dose primary vaccination course Study Listed on
109999 Completed A non-therapeutic study to validate the sampling method to confirm presence of varicella-zoster virus (VZV) DNA by PCR in clinical samples from lesions collected from adults (50 years or older) with clinically diagnosed herpes zoster
110021 Completed Efficacy of GSK Biologicals’ candidate malaria vaccine (257049) against malaria disease caused by P. falciparum infection in infants and children in Africa Study Listed on
110027 Completed A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects with Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium vivax Malaria Patients with Glucose-6-phosphate Dehydrogenase Deficiency
110028 Completed A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant Study Listed on
110031 Completed Phase II, observer-blind follow-up study to assess reacto-and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), when given as booster in primed children or as 2-dose catch-up in unprimed children. Study Listed on
110040 Completed A single-blind, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1070806 in healthy and obese subjects. Study Listed on
110058 Completed Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age. Study Listed on
110071 Completed Immune response to a hepatitis B vaccine challenge dose in healthy subjects who received primary vaccination of GlaxoSmithKline Biologicals' hepatitis B vaccine, approximately 20 years ago. Study Listed on
110073 Completed Study to evaluate the immune response of healthy subjects who received neonatal vaccination course with GSK Biologicals’ Engerix™-B vaccine, approximately 20 years ago. Study Listed on
110080 Completed Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9
110094 Completed A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)
110099 Completed A study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate DPI plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI
110101 Completed Clinical assessment of GW815SF Salmeterol/fluticasone propionate (HFA MDI) in pediatric patients with bronchial asthma -A long term (24-week) study-
110106 Completed A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers. Study Listed on
110127 Completed Safety and immunogenicity study of GSK Biologicals’ cell culture-based influenza virus vaccine 1388442A compared with US licensed TIV in healthy adults Study Listed on
110142 Completed Non-inferiority of co-administration of GSK Biologicals’pneumococcal conjugate vaccine GSK1024850A with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib. Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.